• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Nemaura Pharma appoints Dr. Werner Wessling director of Strategic Alliances

Nemaura Pharma appoints Dr. Werner Wessling director of Strategic Alliances

April 11, 2017
CenterWatch Staff

U.K. biotech company Nemaura Pharma is continuing its growth plans with the appointment of leading global pharmaceutical expert Dr. Werner Wessling. Dr. Wessling will join the management team as director of Strategic Alliances with a remit to expand Nemaura’s commercial partnerships and collaborations in drug formulation and medical device technologies globally.

Dr. Wessling is a highly respected deal-maker and negotiator in pharmaceutical product development, licensing and commercialization. His early career in management with Beiersdorf and Altana subsequently led to his appointment in 1987 as VP Business Development worldwide for LTS Lohmann Therapie-Systeme, a transdermal patch manufacturer. Dr. Wessling subsequently built a successful commercial career with LTS, helping to grow the global pharmaceutical company to become the world’s largest Transdermal Patch manufacturer with 1,300 employees. He was appointed senior VP, Corporate Development, in 2000, a position he held until 2016.

Nemaura CEO Dr. Faz Chowdhury said, “We highly value Dr Wessling’s expertise and strategic industry insight built over 30 years with LTS, and his extensive network will support our ambitious plans for expansion and growth. Our work is already poised to transform the way therapeutic drugs are administered through the skin using our advanced delivery systems, and Dr. Wessling’s arrival will further accelerate our impact as a major global player.”

During his tenure with LTS Lohmann Therapie-Systeme, Dr. Werner Wessling was responsible for multiple licensing and patents negotiations, and for closing deals in Europe, North America and Asia (Japan and Korea). Most of the innovative and profitable products in the current LTS portfolio are a result of Dr. Wessling's skilful negotiation and partnering efforts and have generated more than $10 billion in lifetime marketing partner revenues.

Dr. Wessling commented, “I have accepted the opportunity to work with Dr. Chowdhury because I believe Nemaura’s technologies will be able to solve some of the issues in the effective delivery of Biologics and vaccines. Nemaura’s growth since start-up in 2005 has been impressive. It shows what can be achieved when you build a high-calibre team committed to innovation and to improving patient lifestyle and quality of life.”

The value of the global skin drug delivery market is expected to reach £33 billion by 2018 and Nemaura aims to be one of the leading pharmaceutical technologists in this market.

Upcoming Events

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • tablet

    Digital Intake Platforms Effective as Source of Trial Information, Survey Shows

  • Diversity-360x240.png

    Site Spotlight: EmVenio Research Takes to the Road to Promote Trial Diversity

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing